PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact
B Grubmüller, P Baltzer, S Hartenbach… - Clinical Cancer …, 2018 - AACR
Purpose: Primary staging of prostate cancer relies on modalities, which are limited. We evaluate
simultaneous [ 68 Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method …
simultaneous [ 68 Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method …
Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial
M Hartenbach, S Hartenbach, W Bechtloff, B Danz… - Clinical Cancer …, 2014 - AACR
Purpose: The pretherapeutic assessment of prostate cancer is challenging and still holds
the risk of over- or undertreatment. This prospective trial investigates positron emission …
the risk of over- or undertreatment. This prospective trial investigates positron emission …
[HTML][HTML] [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery
S Rasul, S Hartenbach, K Rebhan, A Göllner… - European Journal of …, 2018 - Springer
Purpose Medullary thyroid carcinoma (MTC) is characterized by a high rate of metastasis. In
this study we evaluated the ability of [ 18 F]DOPA PET/ceCT to stage MTC in patients with …
this study we evaluated the ability of [ 18 F]DOPA PET/ceCT to stage MTC in patients with …
[HTML][HTML] Lymphoepithelial carcinoma of larynx and hypopharynx: a rare clinicopathological entity
M Faisal, S Hartenbach, A Schratter, WJ Köstler… - Cancers, 2020 - mdpi.com
(1) Background: Lymphoepithelial carcinoma of the hypopharynx and larynx is a rare tumor
with fewer than 50 cases in the published literature. We present a literature review to discuss …
with fewer than 50 cases in the published literature. We present a literature review to discuss …
Thyroid and androgen receptor signaling are antagonized by μ‐crystallin in prostate cancer
O Aksoy, J Pencik, M Hartenbach… - … journal of cancer, 2021 - Wiley Online Library
Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate
cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides …
cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides …
Evaluating treatment response of radioembolization in intermediate-stage hepatocellular carcinoma patients using 18F-fluoroethylcholine PET/CT
M Hartenbach, S Weber, NL Albert… - Journal of Nuclear …, 2015 - Soc Nuclear Med
The aim of this study was to evaluate 18 F-fluoroethylcholine PET/CT as a metabolic imaging
technique for the assessment of treatment response to 90 Y radioembolization in patients …
technique for the assessment of treatment response to 90 Y radioembolization in patients …
[HTML][HTML] Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer
…, M Hacker, S Hartenbach, SF Shariat, M Hartenbach… - Current …, 2023 - mdpi.com
Purpose: To investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine
(FMC) and [ 68 Ga]Ga-PSMA HBED-CC conjugate 11 (PSMA)-positron …
(FMC) and [ 68 Ga]Ga-PSMA HBED-CC conjugate 11 (PSMA)-positron …
Combined [18F]-Fluoroethylcholine PET/CT and 99mTc–Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular …
M Hartenbach, S Weber, M Pilz… - Clinical Nuclear …, 2018 - journals.lww.com
Aim The aim of this study was to retrospectively analyze the prognostic value of combined
99m Tc–macroaggregated albumin (MAA) SPECT/CT and [18 F]-fluoroethylcholine (FEC) PET/…
99m Tc–macroaggregated albumin (MAA) SPECT/CT and [18 F]-fluoroethylcholine (FEC) PET/…
Dose-Dependent Uptake of 3′-deoxy-3′-[18 F]Fluorothymidine by the Bowel after Total-Body Irradiation
M Hartenbach, A Delker, S Hartenbach… - Molecular imaging and …, 2014 - Springer
Purpose The aim of this study is to non-invasively assess early, irradiation-induced normal
tissue alterations via metabolic imaging with 3′-deoxy-3′-[ 18 F]fluorothymidine ([ 18 F]FLT)…
tissue alterations via metabolic imaging with 3′-deoxy-3′-[ 18 F]fluorothymidine ([ 18 F]FLT)…
Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer
O Aksoy, J Pencik, M Hartenbach, AA Moazzami… - bioRxiv, 2019 - biorxiv.org
Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate
cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides …
cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides …